Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
894 studies found for:    "Narcotic Antagonists"
Show Display Options
Rank Status Study
1 Recruiting The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams
Condition: Neuroscience of Dreaming, Healthy
Interventions: Drug: Naltrexone;   Other: Placebo
2 Completed Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist
Conditions: ADHD;   Stimulant-Induced Euphoria
Interventions: Drug: SODAS MPH;   Drug: Naltrexone
3 Completed Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity
Condition: Addiction
Interventions: Drug: Placebo;   Drug: Amisulpride;   Drug: Naltrexone
4 Terminated Opioid Agonist and Antagonist Effects on Opioid Dependence
Condition: Opioid-Related Disorders
Interventions: Drug: Methadone;   Drug: Full opioid agonist;   Drug: Partial opioid agonist;   Drug: Opioid antagonist
5 Completed The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism
Condition: Opiate Addiction
Interventions: Drug: Naltrexone;   Drug: Clonidine;   Drug: Lorazepam
6 Completed An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg
Condition: Analgesia
Intervention: Drug: Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.
7 Completed An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg
Condition: Analgesia
Intervention: Drug: OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).
8 Recruiting Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a
Condition: ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Interventions: Drug: CERC-501;   Drug: placebo
9 Recruiting Naloxegol Health Outcomes PASS
Condition: Opioid Induced Constipation
Interventions: Drug: naloxegol;   Drug: non-PAMORA laxative
10 Recruiting Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Conditions: Alcohol Dependence;   Alcohol Use Disorder
Intervention: Drug: XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
11 Terminated Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
Conditions: Obesity;   Overweight
Interventions: Drug: NB32;   Drug: PBO;   Behavioral: Weight Management Program
12 Active, not recruiting Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery
Conditions: Pain, Postoperative;   Postoperative Nausea and Vomiting;   Scoliosis
Intervention: Drug: Naloxone
13 Completed
Has Results
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
Conditions: Neoplasms;   Constipation;   Opioid-Related Disorders
Intervention: Drug: Methylnaltrexone bromide
14 Recruiting Naloxegol US PMR CV Safety
Condition: Opioid Induced Constipation
Interventions: Drug: naloxegol;   Drug: non-PAMORA
15 Unknown  Buprenorphine's Dose Response Curve
Condition: Opioid-related Disorders
Interventions: Drug: Buprenorphine;   Drug: Morphine;   Drug: Placebo
16 Completed Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
Condition: Healthy Males
Interventions: Drug: Naloxone;   Drug: IV Methylnaltrexone (MNTX);   Drug: Placebo
17 Terminated Naltrexone in Borderline Personality Disorder
Condition: Borderline Personality Disorder
Intervention: Drug: Naltrexone
18 Completed Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
Condition: Coronary Artery Disease
Interventions: Drug: Methylnaltrexone;   Other: Placebo;   Drug: Morphine;   Drug: Ticagrelor
19 Not yet recruiting Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL
Conditions: Mycosis Fungoides;   Lymphoma, T-Cell, Cutaneous
Interventions: Drug: Naloxone Hydrochloride Lotion, 0.5%;   Drug: Placebo Lotion
20 Completed Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients
Condition: Opioid Use, Unspecified With Other Opioid-induced Disorder
Intervention: Drug: Methylnaltrexone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years